JP7510874B2 - マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン - Google Patents

マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン Download PDF

Info

Publication number
JP7510874B2
JP7510874B2 JP2020533815A JP2020533815A JP7510874B2 JP 7510874 B2 JP7510874 B2 JP 7510874B2 JP 2020533815 A JP2020533815 A JP 2020533815A JP 2020533815 A JP2020533815 A JP 2020533815A JP 7510874 B2 JP7510874 B2 JP 7510874B2
Authority
JP
Japan
Prior art keywords
antigens
porcine
combination vaccine
dose
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020533815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506874A5 (https=
JP2021506874A (ja
Inventor
ギラルト，ジョルディ モンテイン
モラス，エステル プチヴェルト
サンス，アレキサンドラ モロス
アルナウ，マルタ シトゥハ
Original Assignee
ヒプラ シエンティフィック エセ．エレ．ウ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヒプラ シエンティフィック エセ．エレ．ウ． filed Critical ヒプラ シエンティフィック エセ．エレ．ウ．
Publication of JP2021506874A publication Critical patent/JP2021506874A/ja
Publication of JP2021506874A5 publication Critical patent/JP2021506874A5/ja
Application granted granted Critical
Publication of JP7510874B2 publication Critical patent/JP7510874B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020533815A 2017-12-22 2018-12-19 マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン Active JP7510874B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382893 2017-12-22
EP17382893.0 2017-12-22
PCT/EP2018/085844 WO2019121916A1 (en) 2017-12-22 2018-12-19 Intradermal combination vaccine against mycoplasma and porcine circovirus

Publications (3)

Publication Number Publication Date
JP2021506874A JP2021506874A (ja) 2021-02-22
JP2021506874A5 JP2021506874A5 (https=) 2021-12-02
JP7510874B2 true JP7510874B2 (ja) 2024-07-04

Family

ID=61024548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020533815A Active JP7510874B2 (ja) 2017-12-22 2018-12-19 マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン

Country Status (7)

Country Link
US (1) US11744883B2 (https=)
EP (1) EP3727432A1 (https=)
JP (1) JP7510874B2 (https=)
BR (1) BR112020012483A2 (https=)
CA (1) CA3085535A1 (https=)
MX (1) MX2020006662A (https=)
WO (1) WO2019121916A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11744883B2 (en) * 2017-12-22 2023-09-05 Hipra Scientific, S.L.U. Intradermal combination vaccine against mycoplasma and porcine circovirus
US20220323567A1 (en) * 2019-09-12 2022-10-13 Intervet Inc. Combination vaccine for intradermal administration
CN112294953A (zh) * 2020-12-31 2021-02-02 北京科牧丰生物制药有限公司 一种pcv2型杆状病毒载体、猪肺炎支原体、副猪嗜血杆菌三联灭活疫苗及制备方法
WO2024235714A1 (en) * 2023-05-12 2024-11-21 Intervet International B.V. A vaccine against leptospira bacterium
WO2024235713A1 (en) * 2023-05-12 2024-11-21 Intervet International B.V. A vaccine against erysipelothrix rhusiopathiae and porcine parvo virus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520771A (ja) 2008-01-23 2011-07-21 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
WO2014182872A1 (en) 2013-05-08 2014-11-13 Protatek International, Inc. Vaccine for pcv2 and mycoplasma
JP2015512450A (ja) 2012-04-04 2015-04-27 ゾエティス・エルエルシー Ｐｃｖ／マイコプラズマ・ハイオニューモニエ／ｐｒｒｓ混合ワクチン
WO2017162741A1 (en) 2016-03-23 2017-09-28 Intervet International B.V. A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
EP1968630B1 (en) * 2005-12-29 2018-01-24 Boehringer Ingelheim Vetmedica, Inc. Multivalent pcv2 immunogenic compositions
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
EP2684959A1 (en) 2012-07-10 2014-01-15 Laboratorios Hipra, S.A. Vectors for transforming Mycoplasma hyopneumoniae, transformed M.hyopneumoniae strains, and use thereof
GB201220889D0 (en) 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived peptides for treating metastasizing cancers
EP3037119A1 (en) 2014-12-23 2016-06-29 Hipra Scientific, S.L.U. Device for administering medicinal products
JP6839714B2 (ja) * 2015-12-28 2021-03-10 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド Ｍ Ｈｙｏ多重ワクチン及びその使用
US11744883B2 (en) * 2017-12-22 2023-09-05 Hipra Scientific, S.L.U. Intradermal combination vaccine against mycoplasma and porcine circovirus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011520771A (ja) 2008-01-23 2011-07-21 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド Ｐｃｖ２マイコプラズマ・ハイオニューモニエ免疫原性組成物および前記組成物の製造方法
JP2015512450A (ja) 2012-04-04 2015-04-27 ゾエティス・エルエルシー Ｐｃｖ／マイコプラズマ・ハイオニューモニエ／ｐｒｒｓ混合ワクチン
WO2014182872A1 (en) 2013-05-08 2014-11-13 Protatek International, Inc. Vaccine for pcv2 and mycoplasma
WO2017162741A1 (en) 2016-03-23 2017-09-28 Intervet International B.V. A combination vaccine against pcv2 virus and mycoplasma hyopneumoniae infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
INGELVAC CIRCOFLEX -MYCOFLEX MATERIAL SAFETY DATA SHEET，BOEHRINGER INGELHEIM，2008年06月23日，PAGE(S):1-9，http://www.bi-vetmedica.com/content/dam/internet/ah/vetmedica/com_EN/MSDS/Ingelvac CircoFlex-Mycoflex_msds.pdf

Also Published As

Publication number Publication date
WO2019121916A1 (en) 2019-06-27
US11744883B2 (en) 2023-09-05
CA3085535A1 (en) 2019-06-27
EP3727432A1 (en) 2020-10-28
MX2020006662A (es) 2020-08-31
US20200376106A1 (en) 2020-12-03
JP2021506874A (ja) 2021-02-22
BR112020012483A2 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
JP7510874B2 (ja) マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン
KR102003620B1 (ko) Pcv/마이코플라즈마 하이요뉴모니아 조합 백신
AU2006236711B2 (en) Novel vaccine formulations
AU2013243535C1 (en) Mycoplasma hyopneumoniae vaccine
CA3045563C (en) Combination vaccine for swine
JP2006528647A (ja) 新規ワクチン製剤
BR112014024775B1 (pt) composições imunogênica trivalente e de vacina e seus uso para imunização contra mycoplasma hyopneumoniae, circovírus suíno tipo 2 e vírus da síndrome reprodutiva e respiratória de suíno e método de preparação, bem como kit compreendendo as ditas composições
US10568954B2 (en) Process for ready-to-use PCV/M.Hyo combination vaccine
CN101980720A (zh) Pcv2猪肺炎支原体致免疫组合物及其制备方法
JP6907227B2 (ja) Ｐｃｖ２ウイルス及びマイコプラズマ・ハイオニューモニエ感染症に対する混合ワクチン
CN114364398B (zh) 用于皮内施用的联合疫苗
JP2013223511A (ja) マイコプラズマ・ボビスワクチン
JP2013223511A6 (ja) マイコプラズマ・ボビス ワクチン
US6632439B2 (en) Fusobacterium necrophorum vaccine and method for making such vaccine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211022

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240229

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240624